Inicio › Linfoma de Burkitt › Iowa
Ensayos clínicos de Linfoma de Burkitt en Iowa
8 estudios sobre Linfoma de Burkitt buscan participantes en Iowa.
Ciudades en Iowa
Texto oficial del estudio (inglés)
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Iowa City
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07109219Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic, Clive
- UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines
- y 2 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT03739814A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
ReclutandoFase 2
Edades de 1 a 30 · Todos los sexos · Actualizado el 12 nov 2026 · NCT04546399Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
ReclutandoFase 3
Edades de 18 a 39 · Todos los sexos · Actualizado el 3 nov 2026 · NCT03150693Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Iowa Health Care. ( Site 1017), Iowa City
ReclutandoFase 1/2
6 Months – 25 Years · Todos los sexos · Actualizado el 30 oct 2026 · NCT06395103Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Blank Children's Hospital, Des Moines
ReclutandoFase 2
365 Days · Todos los sexos · Actualizado el 27 oct 2026 · NCT06317662A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
ReclutandoFase 2
366 Days – 46 Years · Todos los sexos · Actualizado el 27 oct 2026 · NCT06124157Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
ReclutandoFase 3
365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.